Walleye Capital LLC Raises Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Walleye Capital LLC lifted its holdings in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) by 334.4% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 119,792 shares of the company’s stock after acquiring an additional 92,217 shares during the period. Walleye Capital LLC owned approximately 0.29% of Vigil Neuroscience worth $407,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Point72 Asset Management L.P. purchased a new stake in shares of Vigil Neuroscience during the second quarter worth about $5,940,000. Vanguard Group Inc. boosted its position in Vigil Neuroscience by 11.9% in the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after buying an additional 95,276 shares during the last quarter. Ensign Peak Advisors Inc boosted its position in Vigil Neuroscience by 72.8% in the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock valued at $1,580,000 after buying an additional 166,442 shares during the last quarter. abrdn plc purchased a new stake in Vigil Neuroscience in the third quarter valued at approximately $799,000. Finally, Renaissance Technologies LLC boosted its position in Vigil Neuroscience by 19.2% in the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after buying an additional 11,536 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Price Performance

Shares of VIGL stock opened at $2.27 on Tuesday. The company has a market cap of $92.80 million, a price-to-earnings ratio of -1.10 and a beta of 1.66. The stock has a 50 day simple moving average of $3.29 and a 200-day simple moving average of $3.58. Vigil Neuroscience, Inc. has a 1-year low of $2.08 and a 1-year high of $6.06.

Wall Street Analyst Weigh In

A number of brokerages recently commented on VIGL. William Blair began coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They issued an “outperform” rating on the stock. Guggenheim dropped their target price on Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Wedbush boosted their price target on Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and issued a $22.00 price target on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Vigil Neuroscience in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.